Table 2.
Biodistribution of CRLX101 in Nude Mice Bearing Subcutaneous, Human LS174T Colorectal Cancer Xenografts
| Tissue \ Time Point | Level of Released, Active CPT (ng/mL or ng/g) | |||
|---|---|---|---|---|
| CRLX101 | CPT | |||
| 24 hrs | 48 hrs | 24 hrs | 48 hrs | |
| Plasma | 72 ± 9 | 3 ± 3 | 0 ± 0 | 0 ± 0 |
| Tumor | 183 ± 115 | 55 ± 22 | 1 ± 0 | 0 ± 0 |
| Liver | 241 ± 132 | 121 ± 57 | 106 ± 40 | 108 ± 74 |
| Spleen | 45 ± 42 | 13 ± 17 | 49 ± 15 | 0 ± 0 |
| Lung | 57 ± 43 | 11 ± 9 | 8 ± 15 | 0 ± 0 |
| Heart | 23 ± 21 | 5 ± 5 | 0 ± 0 | 14 ± 0 |
Plasma and tissue collection at 24 and 48 hours after single-dose administration at respective MTDs (3 mg/kg Intraperitoneally for CPT and 24 mg/kg CPT equivalent dose intravenously for CRLX101). Data are from reference [23].